MaxCyte, Inc. filings document the regulatory record for a Delaware life sciences tools company with Nasdaq-listed common stock. Its Form 8-K disclosures cover operating results and financial condition, corporate presentations, executive appointments, compensatory arrangements, listing-compliance notices, and cost-structure actions tied to workforce and operating changes.
MaxCyte proxy materials cover annual stockholder meeting matters, including director elections, board-class structure and auditor ratification. Together, the filings describe governance, capital-market status, material events, and formal disclosures related to MaxCyte’s cell-engineering platform business, Strategic Platform License model, and public-company reporting obligations.
Hemrajani Rekha, a director of MaxCyte, Inc. (MXCT), reported the sale of 10,684 shares of the issuer's common stock on 06/25/2025 at a weighted average price of $2.0945 per share. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2025. After the reported transactions, the reporting person beneficially owned 39,893 shares, with ownership reported as direct.
The Form 4 indicates the sales occurred in multiple transactions at prices ranging from $2.07 to $2.1212. The reporting person offered to provide detailed breakdowns of share counts by price upon request. No derivative transactions or other securities changes are reported in this filing.
MaxCyte, Inc. filed a Form S-8 to register securities for its employee benefit plans, incorporating by reference its Annual Report on Form 10-K for the year ended December 31, 2024 (filed March 11, 2025), Quarterly Reports on Form 10-Q for periods ended March 31, 2025 and June 30, 2025, certain Form 8-Ks, and its Form 8-A description of common stock. The filing lists exhibits including the 2022 Equity Incentive Plan and the 2021 Employee Stock Purchase Plan, and names executive officers and directors such as Maher Masoud and Douglas Swirsky.
MaxCyte CFO Douglas J. Swirsky reported a non-derivative insider purchase on Form 4: he acquired 50,000 shares of MaxCyte common stock at $1.29 per share on 08/13/2025, increasing his direct beneficial ownership to 161,811 shares. The filing lists the transaction in Table I as a purchase and indicates no derivative securities were reported.
Masoud Maher, who serves as President, CEO and a Director of MaxCyte, Inc. (MXCT), reported the purchase of 75,000 shares on 08/13/2025. The Form 4 discloses the shares were bought in multiple transactions at prices ranging from $1.29 to $1.44, with a reported average price of $1.3722. Following these purchases, Mr. Maher’s direct beneficial ownership increased to 175,000 shares. The filing also states he will provide itemized per-price purchase details on request.
Erck Stanley C, a director of MaxCyte, Inc. (MXCT), purchased 100,000 shares of the company’s common stock on 08/13/2025. The Form 4 shows the purchases were coded as P (purchase) and were made at prices ranging from $1.29 to $1.44, with a reported price entry of $1.3722. After the transactions the reporting person directly beneficially owned 398,328 shares. The filer notes the shares were bought in multiple transactions and offers to provide a detailed breakdown of the number of shares bought at each price upon request. No derivative holdings are reported on the form.
Douglas Richard, a director of MaxCyte, Inc. (MXCT), purchased shares on 08/13/2025. The Form 4 reports an acquisition of 80,000 shares of common stock, increasing his reported beneficial ownership to 230,577 shares held directly. The filing shows a reported price of $1.388 per share with a footnote stating the shares were bought in multiple transactions at prices ranging from $1.30 to $1.40 and that the reporter will provide a detailed breakdown on request. The form is signed by an attorney-in-fact for the reporting person.
Brooke William W, a director of MaxCyte, Inc. (MXCT), reported a purchase of 50,000 shares of common stock on 08/13/2025 at $1.29 per share, bringing his direct beneficial ownership to 150,879 shares. The Form 4 shows no derivative holdings and no amendment date. The filing was signed by an attorney-in-fact, David Sandoval, on 08/13/2025.
MaxCyte, Inc. reported the departure of Ali Soleymannezhad from his role as Chief Commercial Officer. The company states his separation is governed by an Amended and Restated Severance Agreement dated July 1, 2024.
Under that agreement, Mr. Soleymannezhad will receive his base salary for nine months and contributions toward COBRA health care continuation for the nine-month severance period, provided he executes and complies with the agreement's release of claims. The filing references the Severance Agreement filed as exhibit 10.2 to the Company’s Quarterly Report for the quarter ended March 31, 2025. No salary amounts, successor information, or additional operational or financial details were disclosed.